| 0.5599 Data as of May 24 |  -0.0101 / -1.77%Today’s Change | 0.48 Today|||52-Week Range 2.95 | -46.68% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $41.2M |
Company Description
Savient Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. Savient Pharmaceuticals focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. It also manufactures and supplies Oxandrin and CIII in the U.S. Savient Pharmaceuticals operates through only one segment: Specialty Pharmaceutical. The company was founded in 1980 is headquartered in East Brunswick, NJ.
Employees
Shareholders
| Individual stakeholders | 5.10% |
| Other institutional | 25.28% |
| Mutual fund holders | 23.11% |
Top Executives
| Louis Ferrari, MBA | President, Chief Executive Officer & Director |
| Richard Crowley | Chief Operating Officer & Executive Vice President |
| John P. Hamill, CPA | Chief Financial Officer & Senior Vice President |
| Kenneth M. Bahrt, MD | Chief Medical Officer & Senior Vice President |
| Marsha Wolfson, MD | Vice President-Clinical Affairs |
.
